Genetically adjusted PSA levels for prostate cancer screening

Linda Kachuri,Thomas J. Hoffmann,Yu Jiang,Sonja I. Berndt,John P. Shelley,Kerry R. Schaffer,Mitchell J. Machiela,Neal D. Freedman,Wen-Yi Huang,Shengchao A. Li,Ryder Easterlin,Phyllis J. Goodman,Cathee Till,Ian Thompson,Hans Lilja,Stephen K. Van Den Eeden,Stephen J. Chanock,Christopher A. Haiman,David V. Conti,Robert J. Klein,Jonathan D. Mosley,Rebecca E. Graff,John S. Witte
DOI: https://doi.org/10.1038/s41591-023-02277-9
IF: 82.9
2023-06-02
Nature Medicine
Abstract:Prostate-specific antigen (PSA) screening for prostate cancer remains controversial because it increases overdiagnosis and overtreatment of clinically insignificant tumors. Accounting for genetic determinants of constitutive, non-cancer-related PSA variation has potential to improve screening utility. In this study, we discovered 128 genome-wide significant associations ( P < 5 × 10 −8 ) in a multi-ancestry meta-analysis of 95,768 men and developed a PSA polygenic score (PGS PSA ) that explains 9.61% of constitutive PSA variation. We found that, in men of European ancestry, using PGS-adjusted PSA would avoid up to 31% of negative prostate biopsies but also result in 12% fewer biopsies in patients with prostate cancer, mostly with Gleason score <7 tumors. Genetically adjusted PSA was more predictive of aggressive prostate cancer (odds ratio (OR) = 3.44, P = 6.2 × 10 −14 , area under the curve (AUC) = 0.755) than unadjusted PSA (OR = 3.31, P = 1.1 × 10 −12 , AUC = 0.738) in 106 cases and 23,667 controls. Compared to a prostate cancer PGS alone (AUC = 0.712), including genetically adjusted PSA improved detection of aggressive disease (AUC = 0.786, P = 7.2 × 10 −4 ). Our findings highlight the potential utility of incorporating PGS for personalized biomarkers in prostate cancer screening.
biochemistry & molecular biology,cell biology,medicine, research & experimental
What problem does this paper attempt to address?